Gene Expression Profiling To Predict and Assess the Consequences of Therapy-Induced Virus Eradication in Chronic Hepatitis C Virus Infection

Abstract

Systems biology has proven to be a powerful tool to identify reliable predictors of treatment response in chronic hepatitis C virus (HCV) infection. In the present study, we studied patients with chronic HCV infection who responded to interferon (IFN)-based therapy, as evidenced by an absence of HCV RNA at the end of treatment, and focused on two issues that have not received much attention. First, we evaluated whether specific genes or gene expression patterns in blood were able to distinguish responder patients with a viral relapse from responder patients who remained virus negative after cessation of treatment. We found that patients with chronic HCV infection who were sustained responders and relapsers after IFN-based therapy showed comparable baseline clinical parameters and immune compositions in blood. However, at baseline, the gene expression profiles of a set of 18 genes predicted treatment outcome with an accuracy of 94%. Second, we examined whether patients with successful therapyinduced clearance of HCV still exhibited gene expression patterns characteristic of HCV or whether normalization of their transcriptome was observed. We observed that the relatively high expression levels of IFN-stimulated genes (ISGs) in patients with chronic HCV infection prior to therapy were reduced after successful IFN-based antiviral therapy (at 24 weeks of follow-up). These ISGs included the CXCL10, OAS1, IFI6, DDX60, TRIM5, and STAT1 genes. In addition, 1,428 differentially expressed non-ISGs were identified in paired pre-and posttreatment samples from sustained responders, which included genes involved in transforming growth factor beta (TGF-␤) signaling, apoptosis, autophagy, and nucleic acid and protein metabolism. Interestingly, 1,424 genes with altered expression levels in responder patients after viral eradication were identified, in comparison to normal expression levels in healthy individuals. Additionally, aberrant expression levels of a subset of these genes, including the interleukin-32 (IL-32), IL-16, CCND3, and RASSF1 genes, were also observed at baseline. Our findings indicate that successful antiviral therapy for patients with chronic HCV infection does not lead to normalization of their blood transcriptional signature. The altered transcriptional activity may reflect HCV-induced liver damage in previously infected individuals. IMPORTANCETools to predict the efficacy of antiviral therapy for patients with HCV infection are important to select the optimal therapeutic strategy. Using a systems biology approach, we identify a set of 18 genes expressed in blood that predicts the recurrence of HCV RNA after cessation of therapy consisting of peginterferon and ribavirin. This set of genes may be applicable as a useful biomarker in clinical decision-making, since the number of genes included in the predictor is small and the correct prediction rate is high (94%). In addition, we observed that the blood transcriptional profile in patients with chronic HCV infection who were successfully treated is not n...

Staphylococcus aureus Phenol-Soluble Modulins Impair Interleukin Expression in Bovine Mammary Epithelial Cells

“…The role of the newly discovered proinflammatory IL-32 during inflammation and in several types of infections is well documented (33,34). However, to our knowledge there is no informa- were grown for 24 h. The cells were then exposed to LAC (WT) pTX ⌬ 16, to the deletion PSM␣-deficient mutant LAC ⌬psm␣ pTX ⌬ 16, and to the complemented LAC ⌬psm␣ pTX ⌬ ␣1-4 strain, as well as to the PSM-deficient mutant LAC ⌬psm␣␤hld pTX ⌬ 16 and complemented strains LAC ⌬psm␣␤hld pTX ⌬ ␣1-4, LAC ⌬psm␣␤hld pTX ⌬ ␤1-2, and LAC ⌬psm␣␤hld pTX ⌬ hld at an MOI of 80:1 for 24 h. mRNA expression was measured in total RNA preparations by qRT-PCR.…”

Assessment of immune status using blood transcriptomics and potential implications for global health

“…No such treatment modalities are available to date for the treatment of patients with Lupus and the few recent studies have for the most part focused instead on patient stratification [28][29][30]. The number of blood transcriptomic studies investigating patients with hepatitis has also increased steadily over recent years, reaching a count of 29 to date, with studies reporting the characterization of interferon signatures in the blood of patients with hepatitis infection [31][32][33] and the identification of signatures associated with response to therapy [34,35]. But the largest increase has been in the number of publications utilizing blood transcriptome profiling in the context of cancer studies.…”

Codon usage of human hepatitis C virus clearance genes in relation to its expression

“…Table S3 depicts the comparative gene expression of the selected candidate genes across different tissues, including normal liver and cancerous liver (HCC) tissue with respective maximum and median values. 55,56 These highly expressed genes inhibit the function of the hepatitis C virus; in the same way during infection, these genes may not express or function normally. 54 A significant correlation is observed between the median value of gene expression and Nc value (r = −0.17, P < .01) along with a maximum value of gene expression and Nc value (− 0.04, P < .01) across different tissues.…”